Sign Up For FREE
Health After 50 Alerts!

We value your privacy and will never rent your email address

Health After 50

Diabetes Medication Linked to Joint Pain

Comments (0)

The FDA is warning that a class of type 2 diabetes drugs called dipeptidyl peptidase-4 (DPP-4) inhibitors may cause severe joint pain.

The drugs include sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta) and alogliptin (Nesina) taken as either a single-ingredient drug or a multi-ingredient drug combined with other diabetes medicines such as metformin.

The DPP-4 inhibitors have been associated with severe, persistent and sometimes disabling joint pain in 33 reported cases from 2006 through 2013. While the pain can start on the first day of taking medication, it can also take years before symptom onset.The good news is that joint pain typically goes away within one month of discontinuing the drug.

If youíre taking a DPP-4 inhibitor and experiencing unexplained severe joint pain, donít stop taking your medicine. Instead, contact your doctor, who can prescribe an alternative drug.†

Posted in Diabetes on January 28, 2016

Medical Disclaimer: This information is not intended to substitute for the advice of a physician. Click here for additional information: Health After 50 Disclaimer

Notify Me

Would you like us to inform you when we post new Diabetes Health Alerts?

Post a Comment


Health After 50 Alerts registered users may post comments and share experiences here at their own discretion. We regret that questions on individual health concerns to the editors cannot be answered in this space.

The views expressed here do not constitute medical advice, and do not represent the position of Scientific American Health After 50 or Remedy Health Media, LLC, which has no responsibility for any comments posted on this site.

Post a Comment

Already a subscriber?


Forgot your password?

New to Health After 50?

Register to submit your comments.

(example: [email protected])


Forgot Password?

Scientific American White Papers

    2016 Diabetes White Paper

    The Diabetes White Paper teaches you how to manage Type 1 and Type 2 diabetes and avoid complications, such as nerve damage, heart disease, kidney failure, and retinopathy. This comprehensive report explains the basics of how your body metabolizes glucose and reviews the latest medications and tools for monitoring your blood glucose. Includes diagrams, glossary, and recent research.

    Read more or order now

Related Titles:

2016 Vision White Paper

Colin A. McCannel, M.D., F.A.C.S., F.R.C.S.C., is Professor of Clinical Ophthalmology at the Jules Stein Eye Institute, University of California, Los Angeles, and Medical Director of UCLA’s Stein Eye Center–Santa Monica. This comprehensive report is essential reading for anyone affected by a vision disorder, including low vision, cataracts, glaucoma, age related macular degeneration, and diabetic retinopathy.

Read more or order now

Health Topic Pages